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Abstract 
 
We train a neural network to predict chemical toxicity based on gene expression data.  The input to the 
network is a full expression profile collected either in vitro from cultured cells or in vivo from live 
animals.  The output is a set of fine grained predictions for the presence of a variety of pathological 
effects in treated animals.  When trained on the Open TG-GATEs database it produces good results, 
outperforming classical models trained on the same data.  This is a promising approach for efficiently 
screening chemicals for toxic effects, and for more accurately evaluating drug candidates based on 
preclinical data. 
 
 
Introduction 
 
Predicting toxicity is a vital problem in many fields.  One quarter of all drug candidates that reach phase 
II clinical trials ultimately fail because of toxicity[1].  Better methods to predict this in advance would 
spare patients from taking drugs that ultimately prove toxic, as well as saving enormous time and 
money.  Toxic effects from industrial and household chemicals are also a major public health problem.  
Often they are tested only on animals, not humans, but animals can be a poor model for toxicity in 
humans[2].  Better methods to predict human toxicity would have major public health benefits. 
 
Many chemicals cause chronic rather than acute toxicity.  It may take months or years for their effects to 
become apparent.  Better methods to spot the early signs of chronic toxicity before clinical symptoms 
appear would allow clinical trials to be stopped sooner, and also would reduce the risk of toxic effects 
being missed. 
 
Gene expression data is often used for predicting toxicity, since it is easy to obtain and highly 
informative[3].  Usually the prediction is made by an indirect, multistep process.  1. Identify the most 
highly differentially expressed genes between treated and control samples.  2. Compare the list of genes to 
standard ontologies to identify biological pathways affected by the chemical[4].  Alternatively, one may 
compare to lists of genes known to be affected by other compounds[5,6], then assume the new compound 
probably has similar effects to ones that affect similar genes.  Either way, the results are imprecise and 
require substantial human interpretation. 
 
The process also loses information.  The original expression data includes one number per gene per 
sample, but the list of differentially expressed genes includes only a single bit per gene, a huge reduction 
in information content.  This suggests better results could possibly be obtained by methods that directly 
analyze the full expression profile. 
 
Several recent studies attempted to do this, with significant success[7–9].  These studies relied on 
relatively simple machine learning models such as Support Vector Machines (SVMs) and naive Bayes 
classifiers.  They also classified chemicals into only a few coarse grained categories (e.g. “toxic” and 
“nontoxic”), rather than attempting fine grained predictions of the many types of toxicity that can occur. 
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In recent years, deep learning has achieved great success in fields such as computer vision and natural 
language processing, largely replacing classical machine learning models in those fields[10].  This leads 
us to speculate that deep neural networks might also be effective for analyzing gene expression data.  Our 
goal in this work is to create a neural network that takes gene expression profiles as input and outputs 
predictions of toxic effects. 
 
We train and test it with the Open TG-GATEs database[11].  This database contains data on 170 
compounds that were tested in vivo on rats, as well as in vitro on rat and human liver cells.  A full 
expression profile was collected for every experiment.  For the in vivo experiments, liver and kidney 
samples were visually examined and graded on each of several dozen histopathological findings.  Our 
model attempts to directly predict these pathological findings based on either in vivo or in vitro expression 
data.  As described later, our results are highly encouraging. 
 
This study is intended as a proof of concept.  Ultimately, of course, we would like to predict in vivo toxic 
effects in humans, but given the available public datasets, we settle for predicting them in rats.  With 
appropriate data to train on, the method should work equally well for any species. 
 
 
Results 
 
Prediction from in vivo data 
 
We first build a neural network that takes the expression profile of an in vivo sample as input, and outputs 
a number for each of the 15 most common pathological findings.  Open TG-GATEs rates each finding as 
one of six grades.  In order of increasing severity, they are: not present, present, minimal, slight, 
moderate, and severe.  We map these to the integers from 0 to 5 and use them as labels for the model to 
predict.  This means it is a regression model, not a classification model.  It tries to predict the severity of 
each finding, not just whether it is present.  This also eliminates the need for ambiguous judgements about 
which compounds to label as “toxic”.  For each sample, the model tries to predict which pathologies were 
actually present in that particular sample. 
 
The distribution of test set samples is shown in Figure 1 for each pathological finding.  Nearly all of them 
show a clear monotonic relationship between measured and predicted severity.  The model tends to output 
higher values for samples that actually displayed the pathology, and the output value increases with 
increasing severity.  The sole exception is microgranuloma, which shows no correlation between true and 
predicted severities. 
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Fig 1. Distribution of predicted severity (vertical axis) versus experimental severity (horizontal axis) for 
all samples in the test set for each of the predicted pathological findings. 
 
In addition to the neural network, we also trained two classical models on the same data: a linear SVM 
and a random forest (RF).  Table 1 shows the weighted L2 error (which was used as the loss function 
during training) for all three models.  The neural network easily outperforms the classical models, having 
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the lowest error on 13 of the 15 prediction tasks.  This shows its predictions are significantly more 
accurate. 
 
 Loss ROC-AUC 
 NN SVM RF NN SVM RF 
Cellular infiltration 1088 1033 1999 0.973 0.988 0.941 
Change, acidophilic 1438 3072 3766 0.930 0.971 0.686 
Change, eosinophilic 1660 2735 2895 0.818 0.712 0.855 
Deposit, glycogen 1447 5172 4859 0.939 0.647 0.860 
Edema 1366 1990 2820 0.917 0.983 0.906 
Hemorrhage 3707 5567 6318 0.883 0.924 0.720 
Hypertrophy 1045 1752 2132 0.995 0.961 0.980 
Increased mitosis 1981 2826 3151 0.815 0.804 0.906 
Lesion, NOS 2684 4548 5071 0.761 0.812 0.760 
Microgranuloma 1301 2230 2092 - - - 
Necrosis 1119 1549 2107 0.915 0.886 0.864 
Proliferation, Kupffer cell 1733 2313 2435 - - - 
Single cell necrosis 1988 1611 2423 0.865 0.971 0.965 
Swelling 2806 6873 6793 0.952 0.421 0.539 
Vacuolization, cytoplasmic 698 1735 1630 0.916 0.912 0.925 
 
Table 1. Performance on the test set for each of the three models (neural network, support vector machine, 
random forest) on each of the predicted pathological findings.  The best scoring model in each case is 
shown in bold.  ROC-AUC was not computed for two of the findings because there were not sufficient 
test samples rated as "slight" or higher. 
 
Although the models were trained as regression models, it is also informative to see how well they can 
perform classification.  For each pathology we divide the samples into two groups: those rated “minimal” 
or lower, and those rated “slight” or higher.  This division is motivated by observing that even untreated 
samples often display pathologies at the “minimal” level, so “slight” is the lowest level reliably indicating 
a toxic effect. 
 
Table 1 shows the ROC-AUC scores (area under the receiver operating characteristic curve).  The neural 
network again performs best, with a mean AUC over all pathologies of 0.898.  It is followed by the SVM 
with a mean AUC of 0.846, and the RF with a mean AUC of 0.839. 
 
Prediction from in vitro data 
 
We next try to predict pathological findings based on in vitro expression data.  Experiments on cultured 
human cells are inexpensive to perform, and they avoid the many ethical concerns of testing potentially 
toxic chemicals on humans.  An effective prediction model that requires only preclinical data would allow 
better decisions about which drug candidates should advance to clinical trials.  It also would enable fast, 
inexpensive screening of industrial chemicals for potential toxicity. 
 
Since the input values (expression levels) and labels (pathological findings) now come from different 
experiments, some care is required in matching them up.  The in vivo and in vitro data sets both include 
multiple dose levels, and the correspondence between them is ambiguous.  If a pathological finding was 
observed at “slight” or higher level in at least two treated in vivo samples (any dose) for a compound, the 
compound is considered to potentially cause that pathology.  We use only the highest dose level in vitro 
samples, since those are most likely to actually display a toxic effect.  Our neural network takes an in 
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vitro expression profile as input, and predicts whether or not the sample was treated with a drug that 
causes each pathology in vivo. 
 
Clearly this process is imperfect.  Even if a chemical sometimes causes a particular toxic effect, that does 
not guarantee the effect will actually be present in every treated sample.  Our hope is that even when no 
toxic effect is observed, gene expression will still be disrupted enough for the model to recognize that a 
drug could cause a particular effect.  Likewise, when a toxic effect takes time to develop, we hope that 
warning signs of it will be detectable in expression profiles from earlier time points. 
 
As before we train three models: a neural network, a linear SVM, and a random forest.  The ROC-AUC 
scores are shown in Table 2.  The neural network easily outperforms both of the classical models with a 
mean AUC over all pathologies of 0.754, compared to 0.627 for the random forest and only 0.543 for the 
SVM.  In fact, the SVM has minimal predictive ability (AUC below 0.6) for all but one task.  The random 
forest does somewhat better, but it still has minimal predictive ability on four of the nine tasks.  In 
contrast, the neural network has AUC scores above 0.6 for all but one task.  The one task on which all 
models fail, "Deposit, pigment", happens to be the task with the least training data, having only 12 
positive examples in the training set.  There may simply not be sufficient data for any of the models to 
learn this task. 
 
 ROC-AUC 
 NN SVM RF 
Change, eosinophilic 0.802 0.500 0.481 
Deposit, pigment 0.451 0.500 0.522 
Ground glass appearance 0.690 0.583 0.436 
Hypertrophy 0.858 0.583 0.762 
Increased mitosis 0.667 0.663 0.520 
Proliferation, bile duct 0.972 0.500 0.747 
Single cell necrosis 0.759 0.481 0.791 
Swelling 0.937 0.500 0.683 
Vacuolization, cytoplasmic 0.651 0.583 0.705 
 
Table 2. Performance on the test set for each of the three models (neural network, support vector machine, 
random forest) on each of the predicted pathological findings.  The best scoring model in each case is 
shown in bold, except in the one case where all models had negligible predictive ability. 
 
The inferior performance of the SVM and RF models seems to be caused primarily by overfitting.  All 
three models do quite well at predicting the training set (data not shown), with most AUC scores being 
above 0.98.  But they do not generalize well to the test set.  Possibly their performance could be improved 
through regularization, although random forests and SVMs are both designed to be inherently resistant to 
overfitting.  The neural network does a better job of generalizing to data that was not used during training. 
 
Figure 2 shows the neural network’s ROC curve (true positive rate versus false positive rate) for each of 
the nine pathologies.  On some of the tasks (“change, eosinophilic”, “proliferation, bile duct”, and 
“swelling”), the true positive rate saturates to 1.0 when the false positive rate is still at a quite low 
value.  This makes the model particularly effective in cases when it is important to correctly classify all 
toxic compounds, and a moderate number of false positives is acceptable.  For example, this would be the 
case when using the model to screen industrial chemicals and identify ones requiring further study. 
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Fig 2. ROC curve (true positive rate versus false positive rate) for the neural network on each of the 
predicted pathological findings.  Wherever the line is above the diagonal, that indicates the model is doing 
better than would be expected by chance. 
 
 
Discussion 
 
In this work we train a neural network to directly predict toxicity from a complete gene expression 
profile.  Compared to previous studies and to the standard techniques in the field, our method has several 
important benefits. 
 
Our model produces explicit predictions about whether or not compounds are toxic.  This is qualitatively 
different from the conventional methods, whose outputs are lists of affected biological pathways, or 
alternatively lists of known compounds with similar effects on gene expression.  This makes it 
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complementary to them.  For understanding a mechanism of action, a list of affected pathways is very 
valuable information, but it also is complex information that requires much human interpretation.  In 
many situations it is valuable to have explicit predictions about whether a compound is or is not toxic. 
 
Our model operates directly on expression profiles rather than on lists of differentially expressed 
genes.  This gives it the potential to be more accurate.  The transition from expression levels to a list of 
genes involves tremendous loss of information.  In some cases, small changes in the expression of many 
genes may be a better predictor than large changes in just a few genes, but conventional methods cannot 
detect it. 
 
Compared to other studies that have tried to directly predict toxicity from expression, our model’s 
predictions are much more detailed and fine grained.  For example, in Liu et al.[7] each compound was 
simply labeled as toxic or non-toxic for each of the studied organs.  In Takahashi et al.[9] each compound 
was placed into one of three categories: genotoxic carcinogens, non-genotoxic carcinogens, and 
neurotoxins.  In contrast, our model independently predicts many different pathological features, thus 
giving more detailed information about the likely effects of a compound. 
 
We use a neural network, in contrast to the simpler classical models used in other studies.  In our tests this 
leads to a substantial improvement in the accuracy of predictions. 
 
We see two primary applications for this method.  First, it can be used to predict clinical toxicity based on 
preclinical data collected from cultured cells.  This will allow a fast, inexpensive assay to screen for toxic 
effects and identify chemicals requiring further study, or promising drug candidates for human trials.  
Second, it can be used to identify early signs of chronic toxicity in either clinical or preclinical 
studies.  This will allow faster and more reliable identification of toxicity, thus saving time, money, and 
human suffering.  Our results are very encouraging for its ability to perform these functions. 
 
The main challenge in applying this method will be the creation or identification of appropriate data sets 
for training.  In this work we apply it to predicting toxicity in rats because of the public availability of 
high quality data.  Ultimately, of course, our goal is to predict toxicity in humans.  The model is 
completely generic with respect to species and should work just as well for humans as for rats.  To do 
that, it needs a large collection of expression data from normal and pathological human samples, along 
with high quality labels for any pathologies present in each sample. 
 
 
Methods 
 
Model for in vivo data 
 
The data set consists of all single-dose in vivo rat liver samples from the Open TG-GATEs database[11].  
This is a total of 7378 samples treated with 158 compounds.  Each sample is graded on several dozen 
pathological findings, but most findings are only observed for a very small number of samples, or in 
many cases never observed at all.  To ensure sufficient data for training and testing, we use only the 15 
most common findings, shown in Table 3.  Each of them is present in at least ten samples, and is observed 
for at least three different compounds. 
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Pathological 
Finding 
Training 
Samples 
Test 
Samples 
Training Compounds Test Compounds 
Cellular 
infiltration 112 19 
LPS, acetaminophen, allyl alcohol, bendazac, 
bromobenzene, carbamazepine, carbon 
tetrachloride, cimetidine, clofibrate, ethionine, 
galactosamine, glibenclamide, griseofulvin, 
hexachlorobenzene, isoniazid, lornoxicam, 
methylene dianiline, phorone, sulfasalazine, 
terbinafine, valproic acid 
acetamidofluorene, 
naphthyl isothiocyanate, 
thioacetamide 
 
Change, 
acidophilic 10 3 
N-nitrosomorpholine, cyclosporine A nitrosodiethylamine 
Change, 
eosinophilic 90 47 
LPS, acetaminophen, aflatoxin B1, bortezomib, 
chlormezanone, coumarin, diethyl maleate, 
ethionamide, ethionine, nicotinic acid, 
omeprazole, phorone 
cycloheximide, 
phenylanthranilic acid, 
thioacetamide 
Deposit, 
glycogen 20 5 
chlormadinone, nicotinic acid bromoethylamine 
Edema 45 7 LPS, methylene dianiline naphthyl isothiocyanate 
Hemorrhage 22 5 methylene dianiline, sulfasalazine phalloidin 
Hypertrophy 39 8 
LPS, bortezomib, bromobenzene, ethionamide, 
imipramine, methapyrilene, methylene dianiline, 
methyltestosterone, puromycin aminonucleoside, 
sulindac 
benzbromarone, 
thioacetamide 
Increased mitosis 92 39 
3-methylcholanthrene, WY-14643, bendazac, 
benziodarone, coumarin, diethyl maleate, 
ethambutol, ethinylestradiol, ethionamide, 
fenofibrate, flutamide, gemfibrozil, griseofulvin, 
ibuprofen, ketoconazole, methyltestosterone, 
nifedipine, papaverine, phorone, propylthiouracil, 
simvastatin 
colchicine, danazol, 
nimesulide, 
phenylanthranilic acid 
Lesion,NOS 9 5 
benziodarone, gefitinib imatinib, 
methanesulfonate salt, 
phalloidin 
Microgranuloma 73 19 
acarbose, ajmaline, bendazac, benziodarone, 
buthionine sulfoximine, captopril, 
chloramphenicol, cimetidine, ciprofloxacin, 
desmopressin acetate, ethinylestradiol, 
ethionamide, etoposide, fluoxetine hydrochloride, 
flutamide, glibenclamide, lornoxicam, 
tetracycline 
colchicine, ethanol, 
nimesulide 
Necrosis 174 20 
3-methylcholanthrene, LPS, WY-14643, 
acarbose, ajmaline, allopurinol, allyl alcohol, 
amiodarone, amitriptyline, amphotericin B, 
aspirin, bendazac, benziodarone, bortezomib, 
bromobenzene, buthionine sulfoximine, captopril, 
carbon tetrachloride, chloramphenicol, 
chlormezanone, chlorpromazine, ciprofloxacin, 
clofibrate, dantrolene, desmopressin acetate, 
diclofenac, diethyl maleate, diltiazem, 
ethinylestradiol, ethionamide, ethionine, 
etoposide, fluoxetine hydrochloride, flutamide, 
furosemide, galactosamine, gemfibrozil, 
glibenclamide, griseofulvin, hexachlorobenzene, 
indomethacin, isoniazid, lomustine, metformin, 
methyldopa, methylene dianiline, nitrofurazone, 
omeprazole, pemoline, phenobarbital, phorone, 
simvastatin, sulfasalazine, tannic acid, terbinafine, 
valproic acid 
colchicine, imatinib, 
methanesulfonate salt, 
naphthyl isothiocyanate, 
nimesulide, 
nitrosodiethylamine, 
phalloidin, 
phenylanthranilic acid, 
tamoxifen, thioacetamide 
Proliferation, 
Kupffer cell 6 5 
chlorpropamide, puromycin aminonucleoside, 
theophylline 
rosiglitazone maleate 
Single cell 
necrosis 142 63 
3-methylcholanthrene, LPS, N-nitrosomorpholine, 
WY-14643, aflatoxin B1, bortezomib, coumarin, 
diethyl maleate, ethionamide, galactosamine, 
colchicine, cycloheximide, 
nitrosodiethylamine, 
phalloidin, thioacetamide 
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gefitinib, methapyrilene, methylene dianiline, 
phorone, tunicamycin 
Swelling 36 45 LPS, aspirin, isoniazid acetamidofluorene, nitrosodiethylamine 
Vacuolization, 
cytoplasmic 54 4 
bendazac, bortezomib, dexamethasone, diethyl 
maleate, enalapril, ethionine, lomustine, 
phenylbutazone, phorone, rifampicin, simvastatin, 
tetracycline 
colchicine, cycloheximide 
 
Table 3. The pathological findings predicted by the in vivo model.  For each one, the table lists the 
specific training and test compounds for which the finding was observed, as well as the total numbers of 
training and test samples in which it was observed. 
 
We divide the samples by compound into training (142 compounds) and test (16 compounds) sets.  This 
ensures that all treated samples in the test set are for compounds not present in the training data.  The 
choice of which compounds to include in each set is highly constrained by the requirement that every 
pathology be present in at least two training compounds and at least one test compound, so as to have 
sufficient data for training and testing. 
 
The model is a fully connected neural network with two hidden layers of width 4000 and 2000, 
respectively[10].  The input is the normalized log scale expression values for 14,075 rat genes, and the 
output is a list of 15 numbers giving the predicted severities for the 15 pathological findings.  All layers 
except the output use rectified linear unit (ReLU) activation and 50% dropout[12] during training.  The 
model is trained to reproduce the measured severities (not present=0, present=1, minimal=2, slight=3, 
moderate=4, severe=5) using an Adam optimizer[13] with batch size 500 for 2000 epochs.  The loss 
function is L2 error, weighted so that the total weight of positive and negative samples is equal for each 
pathology.  The learning rate is initially set to 5×10-5, then decayed by multiplying it by 0.9 every 2000 
steps. 
 
Model for in vitro data 
 
The data set consists of all in vitro rat samples from Open TG-GATEs for which the dose is listed as 
either "Control" or "High".  The list of compounds is restricted to those which were measured in both in 
vitro and in vivo experiments.  This yields a total of 840 control samples and 830 treated samples for 140 
compounds.  We use the same 16 compounds as before for the test set, leaving 124 compounds for the 
training set. 
 
As described previously, the identification of which compounds produce which pathologies is based on 
the observed findings for in vivo liver samples.  If a pathological finding is present at “slight” or higher 
level in at least two treated samples (any dose) for a compound, that compound is considered to cause the 
pathology.  We restrict the dataset to those pathologies caused by at least two training compounds and at 
least one test compound.  This yields nine pathologies, shown in Table 4. 
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Pathological 
Finding 
Training 
Samples 
Test 
Samples 
Training Compounds Test Compounds 
Change, 
eosinophilic 96 6 
acetaminophen, adapin, amiodarone, bucetin, 
chlormezanone, clomipramine, cycloheximide, 
disopyramide, ethambutol, ethinylestradiol, ethionamide, 
ethionine, nicotinic acid, omeprazole, phenylanthranilic 
acid, phorone 
aspirin 
Deposit, 
pigment 12 6 ethambutol, iproniazid methapyrilene 
Ground glass 
appearance 36 12 
benzbromarone, dantrolene, ethambutol, 
hexachlorobenzene, nimesulide, phenobarbital 
papaverine, 
promethazine 
Hypertrophy 222 42 
WY-14643, amitriptyline, bendazac, benzbromarone, 
benziodarone, bromobenzene, bromoethylamine, caffeine, 
carbamazepine, chlormezanone, chlorpropamide, coumarin, 
dantrolene, diazepam, disulfiram, erythromycin 
ethylsuccinate, ethambutol, flutamide, hexachlorobenzene, 
ketoconazole, lomustine, methimazole, methyltestosterone, 
mexiletine, monocrotaline, naproxen, nimesulide, 
omeprazole, phenacetin, phenobarbital, phenytoin, 
quinidine, terbinafine, thioacetamide, ticlopidine, 
tolbutamide, vitamin A 
chloramphenicol, 
diltiazem, 
hydroxyzine, 
imipramine, 
methapyrilene, 
papaverine, 
promethazine 
Increased 
mitosis 78 18 
WY-14643, colchicine, diethyl maleate, ethambutol, 
ethionamide, fenofibrate, gemfibrozil, ibuprofen, 
ketoconazole, methyltestosterone, phorone, puromycin 
aminonucleoside, simvastatin 
danazol, 
methapyrilene, 
papaverine 
Proliferation, 
bile duct 30 6 
acetamidofluorene, lomustine, naphthyl isothiocyanate, 
phalloidin, thioacetamide methapyrilene 
Single cell 
necrosis 48 12 
colchicine, cycloheximide, ethambutol, ethionamide, 
galactosamine, phalloidin, theophylline, thioacetamide 
methapyrilene, 
tunicamycin 
Swelling 36 6 acetamidofluorene, clofibrate, griseofulvin, isoniazid, nitrosodiethylamine, sulfasalazine aspirin 
Vacuolization, 
cytoplasmic 54 12 
amiodarone, amitriptyline, bromoethylamine, 
ethinylestradiol, ethionamide, hexachlorobenzene, 
ketoconazole, phorone, vitamin A 
hydroxyzine, 
imipramine 
 
Table 4. The pathological findings predicted by the in vitro model.  For each one, the table lists the 
specific training and test compounds for which the finding was observed, as well as the total numbers of 
training and test samples treated with those compounds. 
 
The model is a fully connected neural network with two hidden layers of width 4000 and 2000, 
respectively.  The input is the normalized log scale expression values for 14,075 rat genes, and the output 
is a list of nine pairs of numbers giving the predicted probability that each of the nine pathological 
findings is or is not present in the sample.  All layers except the output use ReLU activation and 50% 
dropout during training.  The output layer uses softmax activation to produce values that can be 
interpreted as probabilities.  The model is trained to reproduce a set of labels that equal 1 if a sample was 
treated with a compound that causes the corresponding pathology, 0 otherwise.  Training uses an Adam 
optimizer with batch size 500 for 5000 epochs.  The loss function is the cross entropy between outputs 
and labels, weighted so that the total weight of positive and negative samples is equal for each pathology.  
The learning rate is initially set to 2×10-5, then decayed by multiplying it by 0.9 every 1000 steps. 
 
Implementation 
 
RMA normalization[14] of the expression data is performed with the pyAffy library[15] using the 
Rat2302_Rn_ENTREZG_22.0.0 CDF file from the BrainArray website[16].  The models are 
implemented with DeepChem 2.1[17], TensorFlow 1.7[18], and scikit-learn 0.19.1[19].  Training is 
performed on a NVIDIA Titan X GPU. 
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